» Articles » PMID: 32336230

Pulmonary Hypertension Due to Left Heart Disease: Diagnosis, Pathophysiology, and Therapy

Overview
Journal Hypertension
Date 2020 Apr 28
PMID 32336230
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Pulmonary hypertension (PH) due to left heart disease (LHD) is the most common type of PH and is defined as mean pulmonary artery systolic pressure of >20 mm Hg and pulmonary capillary wedge pressure >15 mm Hg during right heart catheterization. LHD may lead to elevated left atrial pressure alone, which in the absence of intrinsic pulmonary vascular disease will result in PH without changes in pulmonary vascular resistance. Persistent elevation in left atrial pressure may, however, also be associated with subsequent pulmonary vascular remodeling, vasoconstriction, and an increase in pulmonary vascular resistance. Hence, there are 2 subgroups of PH due to LHD, isolated postcapillary PH and combined post- and precapillary PH, with these groups have differing clinical implications. Differentiation of pulmonary arterial hypertension and PH due to LHD is critical to guide management planning; however, this may be challenging. Older patients, patients with metabolic syndrome, and patients with imaging and clinical features consistent with left ventricular dysfunction are suggestive of LHD etiology rather than pulmonary arterial hypertension. Hemodynamic measures such as diastolic pressure gradient, transpulmonary gradient, and pulmonary vascular resistance may assist to differentiate pre- from postcapillary PH and offer prognostic insights. However, these are influenced by fluid status and heart failure treatment. Pulmonary arterial hypertension therapies have been trialed in the treatment with concerning results reflecting disease heterogeneity, variation in inclusion criteria, and mixed end point criteria. The aim of this review is to provide an updated definition, discuss possible pathophysiology, clinical aspects, and the available treatment options for PH due to LHD.

Citing Articles

Sacubitril/valsartan on right ventricular-pulmonary artery coupling and albumin-bilirubin score in heart failure in Chinese patients with reduced ejection fraction.

Shi Y, Gao C, Xu Y, Yuan F J Cardiothorac Surg. 2025; 20(1):72.

PMID: 39833911 PMC: 11749358. DOI: 10.1186/s13019-024-03224-6.


Hormone Replacement Therapy and Pulmonary Hypertension: A Review of the Literature.

Gill N, Sohi S, Joseph G, Bhatti N Cureus. 2024; 16(10):e71908.

PMID: 39564039 PMC: 11576071. DOI: 10.7759/cureus.71908.


Pulmonary Hypertension: Pharmacological and Non-Pharmacological Therapies.

Tsai J, Malik S, Tjen-A-Looi S Life (Basel). 2024; 14(10).

PMID: 39459565 PMC: 11509317. DOI: 10.3390/life14101265.


Right ventricular function in mitral stenosis: plays a fundamental role.

Sari N, Soesanto A J Echocardiogr. 2024; 22(4):185-192.

PMID: 39368011 DOI: 10.1007/s12574-024-00663-x.


Intravenous Levosimendan versus Inhalational Milrinone in the Management of Pulmonary Hypertension during Adult Cardiac Surgery: A Randomized Clinical Trial.

Ftikos P, Gkantinas G, Karageorgos V, Smirli A, Kogerakis N, Leontiadis E Life (Basel). 2024; 14(9).

PMID: 39337947 PMC: 11433114. DOI: 10.3390/life14091164.